Naz Rahman
Stock Analyst at Maxim Group
(0.29)
# 4,378
Out of 5,148 analysts
36
Total ratings
19.35%
Success rate
-43.47%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SCNX Scienture Holdings | Initiates: Buy | $1.5 | $0.42 | +258.34% | 1 | Feb 24, 2026 | |
| KZIA Kazia Therapeutics | Maintains: Buy | $15 → $20 | $8.83 | +126.50% | 1 | Oct 2, 2025 | |
| AYTU Aytu BioPharma | Maintains: Buy | $9 → $7 | $2.64 | +165.15% | 2 | Sep 25, 2025 | |
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $0.62 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $9.07 | +87.43% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $135 → $75 | $1.73 | +4,235.26% | 2 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $33.34 | +109.96% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $0.85 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $6.54 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $1.81 | +341.99% | 7 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.93 | - | 2 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $45 | $11.77 | +282.33% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $8.52 | +1,543.19% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $486.03 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.28 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.13 | +430.97% | 1 | Feb 25, 2022 |
Scienture Holdings
Feb 24, 2026
Initiates: Buy
Price Target: $1.5
Current: $0.42
Upside: +258.34%
Kazia Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $8.83
Upside: +126.50%
Aytu BioPharma
Sep 25, 2025
Maintains: Buy
Price Target: $9 → $7
Current: $2.64
Upside: +165.15%
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.62
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $9.07
Upside: +87.43%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $135 → $75
Current: $1.73
Upside: +4,235.26%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $33.34
Upside: +109.96%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.85
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $6.54
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $1.81
Upside: +341.99%
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $2.93
Upside: -
Jul 26, 2024
Initiates: Buy
Price Target: $45
Current: $11.77
Upside: +282.33%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $8.52
Upside: +1,543.19%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $486.03
Upside: -
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.28
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $1.13
Upside: +430.97%